Sarcopenia and Cirrhosis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02132962

Enrollment

Registered

2014-05-07

Start date

2014-05-31

Completion date

Unknown

Last updated

2015-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis

Brief summary

The study investigates the effect of aminoacid infusion on proteinturnover in muscle from cirrhosis subjects, compared to healthy controls. The hypothesis is that aminoacid infusion can attenuate the increase in proteindegradation that follows cirrhosis.

Interventions

DIETARY_SUPPLEMENTAmino acid infusion

OTHERBloodsamples, Biopsies.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

30 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Male subjects * Diagnosis of cirrhosis, Child-Pugh A, B, C.

Exclusion criteria

* Acute illness within 3 weeks * Ascites collections within 10 days * Heart-, kidney, pulmonary disease. Cancer. Type 1 diabetes. * Active alkoholdrinking

Design outcomes

Primary

Measure	Time frame	Description
Turnover of phenylalanine and tyrosine in skeletal muscle tissue during amino acid infusion. Inflammatory markers. Protein signaling cascade.	24 weeks	Using stable isotope tracer technique with infusion of phenylalanine and tyrosine tracer. Using ELISA technique. Using PCR and western blot technique.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026